Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; and Takeda Oncology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

17th Annual Winter Lung Cancer Conference™

Release Date: March 31, 2020
Expiration Date: March 31, 2021

Activity Overview

Community Practice Connections™: 17th Annual Winter Lung Cancer Conference® consists of a series of interactive clinical vignettes, short video interviews of leading experts in lung cancer, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; and Takeda Oncology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward oncologists involved in the treatment and management of patients with lung cancers. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, fellows, and other health care professionals interested in the treatment of lung cancers may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Integrate molecular testing strategies to inform treatment selection in patients with oncogene-driven non–small cell lung cancer (NSCLC)
  • Evaluate emerging approaches in patient selection for immunotherapy and targeted agents
  • Assess treatment strategies for early-stage and locally advanced lung cancer
  • Describe the use of cytotoxic, targeted, and other systemic agents in the management of patients with lung cancer with or without oncogenic drivers
  • Incorporate immunotherapeutic strategies in patients with thoracic malignancies along the disease continuum
  • Discuss approaches to mitigate and manage treatment-related adverse events in patients with lung cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Jamie E. Chaft, MD
Jamie E. Chaft, MD
Assistant Attending
Thoracic Oncology service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: Genentech, AstraZeneca, Merck, Bristol-Myers Squibb.

Rogerio C. Lilenbaum, MD
Rogerio C. Lilenbaum, MD
Director of Banner
MD Anderson Cancer Center
Phoenix, AZ

Disclosures: Consultant: AstraZeneca; Genentech.

Gilberto de Lima Lopes Junior, MD, MBA, FAMS
Gilberto de Lima Lopes Junior, MD, MBA, FAMS
Associate Professor of Clinical Medicine
Medical Director for International Programs
Associate Director for Global Oncology
Co-Leader, Lung Cancer Site Disease Group
Sylvester Comprehensive Cancer Center at the University of Miami
and the Miller School of Medicine
Miami, FL

Disclosures: Grant Research Support: Merck (MSD), Merck (Serono), Novartis, Tesaro.

Heather A. Wakelee, MD
Heather A. Wakelee, MD
Professor of Medicine (Oncology)
Stanford University Medical Center
Stanford, CA

Disclosures: Grant Research Support: Genentech/Roche, Pfizer, Lilly, Celgene, Exelixis, Novartis, Clovis Oncology, Xcovery, Bristol-Myers Squibb, Merck, Arrys Therapeutics; Consultant: Mirati; Other: Steering committee participant/unpaid adviser: Genentech/Roche, Merck.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
282930
Filter By